Engineered immune cells take aim at deadliest lung cancer

NCT ID NCT07509034

First seen Apr 11, 2026 · Last updated Apr 28, 2026 · Updated 2 times

Summary

This early-phase study tests a new treatment for people with extensive-stage small cell lung cancer or similar neuroendocrine cancers that did not respond to or came back after standard therapy. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack a protein called B7-H3 found on cancer cells. Up to 40 adults will receive the modified cells after a short course of chemotherapy, and researchers will monitor safety and tumor response for up to 15 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.